A Phase 1/2 interventional study of RSV/hMPV_V low dose vaccine and RSV/hMPV_V medium dose vaccine in Respiratory Syncytial Virus Infections+Metapneumovirus, sponsored by GlaxoSmithKline. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline — 1 open to participants now, 5 under way, 3 of them phase 3. Respiratory Syncytial Virus Infections · GlaxoSmithKline.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 11th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 1/2, and was the 40th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline is open now, in 2 countries.
By country, each count listing its studies:
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 13 · Phase 3 21
First in 2013; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 1,456 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 642 across the 40 interventional studies. Of the 33 that completed or were terminated, 30 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07092865GlaxoSmithKlineA Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant | 2027-01-12 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination vaccine and investigational hMPV vaccine in younger and older adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants are eligible to be included in the study only if all of the following criteria apply:
Specific inclusion criteria for OA
Specific inclusion criteria for YA
Participant of childbearing potential may be enrolled in the study if the participant:
Exclusion criteria:
Participants are excluded from participating in the study if any of the following criteria apply:
Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the study.
Up to 3 months prior to the study intervention administration:
Specific exclusion criteria for OA population
At screening (Phase 1 only), participants with:
>=Grade 2 abnormalities for the following parameters, regardless of clinical significance, should be excluded:
Specific exclusion criteria for YA population
At screening, participants with:
>=Grade 2 abnormalities for the following parameters, regardless of clinical significance, should be excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
YA participants receive a single dose of RSV/hMPV\_X low dose vaccine in Phase 1, at Day 1.
Biological: RSV/hMPV_X low dose vaccine
YA participants receive a single dose of RSV/hMPV\_X medium dose vaccine in Phase 1, at Day 1.
Biological: RSV/hMPV_X medium dose vaccine
YA participants receive a single dose of RSV/hMPV\_X high dose vaccine in Phase 1, at Day 1.
Biological: RSV/hMPV_X high dose vaccine
YA participants receive a single dose of hMPV\_Y high dose vaccine in Phase 1, at Day 1.
Biological: hMPV_Y high dose vaccine
YA participants receive a single dose of hMPV\_Z low dose vaccine in Phase 1, at Day 1.
Biological: hMPV_Z low dose vaccine
YA participants receive a single dose of hMPV\_Z medium dose vaccine in Phase 1, at Day 1.
Biological: hMPV_Z medium dose vaccine
YA participants receive a single dose of hMPV\_Z high dose vaccine in Phase 1, at Day 1.
Biological: hMPV_Z high dose vaccine
YA participants receive a single dose of control vaccine in Phase 1, at Day 1.
Biological: Control vaccine
YA participants receive a single dose of placebo in Phase 1, at Day 1.
Combination Product: Placebo
OA participants receive a single dose of RSV/hMPV\_V low dose vaccine in both Phase 1 and Phase 2, at Day 1.
Biological: RSV/hMPV_V low dose vaccine
OA participants receive a single dose of RSV/hMPV\_V medium dose vaccine in both Phase 1 and Phase 2, at Day 1.
Biological: RSV/hMPV_V medium dose vaccine
OA participants receive a single dose of RSV/hMPV\_V high dose vaccine in both Phase 1 and Phase 2, at Day 1.
Biological: RSV/hMPV_V high dose vaccine
OA participants receive a single dose of RSV/hMPV\_W low dose vaccine in both Phase 1 and Phase 2, at Day 1.
Biological: RSV/hMPV_W low dose vaccine
OA participants receive a single dose of RSV/hMPV\_W medium dose vaccine in both Phase 1 and Phase 2, at Day 1.
Biological: RSV/hMPV_W medium dose vaccine
OA participants receive a single dose of RSV/hMPV\_W high dose vaccine in both Phase 1 and Phase 2, at Day 1.
Biological: RSV/hMPV_W high dose vaccine
OA participants receive a single dose of RSV/hMPV\_X low dose vaccine in both Phase 1 and Phase 2, at Day 1.
Biological: RSV/hMPV_X low dose vaccine
OA participants received a single dose of RSV/hMPV\_X medium dose vaccine in both Phase 1 and Phase 2, at Day 1.
Biological: RSV/hMPV_X medium dose vaccine
OA participants receive a single dose of RSV/hMPV\_X high dose vaccine in both Phase 1 and Phase 2, at Day 1.
Biological: RSV/hMPV_X high dose vaccine
OA participants receive a single dose of hMPV\_Y low dose vaccine in Phase 1, at Day 1.
Biological: hMPV_Y low dose vaccine
OA participants receive a single dose of hMPV\_Y medium dose vaccine in both Phase 1 and Phase 2, at Day 1.
Biological: hMPV_Y medium dose vaccine
OA participants receive a single dose of hMPV\_Y high dose vaccine in both Phase 1 and Phase 2, at Day 1.
Biological: hMPV_Y high dose vaccine
OA participants receive a single dose of hMPV\_Z low dose vaccine in Phase 1, at Day 1.
Biological: hMPV_Z low dose vaccine
OA participants receive a single dose of hMPV\_Z medium dose vaccine in Phase 1, at Day 1.
Biological: hMPV_Z medium dose vaccine
OA participants receive a single dose of hMPV\_Z high dose vaccine in Phase 1, at Day 1.
Biological: hMPV_Z high dose vaccine
OA participants receive a single dose of control vaccine in both Phase 1 and Phase 2, at Day 1.
Biological: Control vaccine
OA participants receive a single dose of placebo in both Phase 1 and Phase 2, at Day 1.
Combination Product: Placebo
RSV/hMPV\_V low dose vaccine administered intramuscularly.
RSV/hMPV\_V medium dose vaccine administered intramuscularly.
RSV/hMPV\_V high dose vaccine administered intramuscularly.
RSV/hMPV\_W low dose vaccine administered intramuscularly.
RSV/hMPV\_W medium dose vaccine administered intramuscularly.
RSV/hMPV\_W high dose vaccine administered intramuscularly.
RSV/hMPV\_X low dose vaccine administered intramuscularly.
RSV/hMPV\_X medium dose vaccine administered intramuscularly.
RSV/hMPV\_X high dose vaccine administered intramuscularly.
hMPV\_Y low dose vaccine administered intramuscularly.
hMPV\_Y medium dose vaccine administered intramuscularly.
hMPV\_Y high dose vaccine administered intramuscularly.
hMPV\_Z low dose vaccine administered intramuscularly.
hMPV\_Z medium dose vaccine administered intramuscularly.
hMPV\_Z high dose vaccine administered intramuscularly.
Control vaccine administered intramuscularly.
Placebo administered intramuscularly.
Number of Participants Reporting Solicited Administration Site Events
Solicited administration site events include pain, redness (erythema) and swelling at administration site.
Time frame: Day 1 to Day 7
Number of Participants Reporting Solicited Systemic Events
Solicited systemic events include fever \[defined as oral or axillary temperature greater than or equal to (\>=) 38.0°C/100.4°F\], headache, myalgia (muscle pain), arthralgia (joint pain) and fatigue (tiredness).
Time frame: Day 1 to Day 7
Number of Participants Reporting Unsolicited Adverse Events (AEs)
An unsolicited AE is defined as an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow up for solicited events. Unsolicited AEs include both serious and non-serious AEs.
Time frame: Day 1 to Day 30
Number of Participants Reporting Medically Attended Adverse Events (MAAEs)
MAAE is defined as unscheduled visit to or from healthcare professional for any reason, including emergency room visits.
Time frame: Day 1 to Month 12
Number of Participants Reporting Potential immune-mediated disorders (pIMDs)
pIMDs are a subset of AEs of Special Interest (AESIs) that include autoimmune disorders and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: Day 1 to Month 12
Number of Participants Reporting Serious Adverse Events (SAEs)
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is an abnormal pregnancy outcome, or is a suspected transmission of any infectious agent via an authorized medicinal product.
Time frame: Day 1 to study end [Month 24 for OA groups (only the selected formulation group & its comparators) and Month 12 for all other YA groups & OA groups]
Number of Participants Reporting Hematological and Biochemical Laboratory Abnormalities
Time frame: At Day 1 (pre-vaccination) in Phase 1 groups
Number of Participants Reporting Hematological and Biochemical Laboratory Abnormalities
Time frame: At Day 8 (post-vaccination) in Phase 1 groups
Number of participants with hMPV neutralization titers equal to or above (>=) the assay cut-off value
Time frame: At Day 1 (pre-vaccination), Day 8 and Day 31 in OA groups included in both Phase 1 and Phase 2
Geometric mean titers (GMTs) of hMPV neutralization titers
Time frame: At Day 1 (pre-vaccination), Day 8 and Day 31 in OA groups included in both Phase 1 and Phase 2
Mean geometric increase (MGI) of hMPV neutralization titers
Time frame: At Day 8 and Day 31 compared to Day 1 (pre-vaccination) in OA groups included in both Phase 1 and Phase 2
Seroresponse rate (SRR) against hMPV
SRR is defined as the number of participants having \>=4-fold increase post-vaccination in neutralization titers against hMPV.
Time frame: At Day 8 and Day 31 compared to Day 1 (pre-vaccination) in OA groups included in both Phase 1 and Phase 2
Number of participants with RSV-A neutralization titers >= assay cut-off value
Time frame: At Day 1 (pre-vaccination), Day 8 and Day 31 in OA groups included in both Phase 1 and Phase 2
GMTs of RSV-A neutralization titers
Time frame: At Day 1 (pre-vaccination), Day 8 and Day 31 in OA groups included in both Phase 1 and Phase 2
MGI of RSV-A neutralization titers
Time frame: At Day 8 and Day 31 compared to Day 1 (pre-vaccination) in OA groups included in both Phase 1 and Phase 2
SRR against RSV-A
SRR is defined as number of participants having \>=4-fold-increase post-vaccination in neutralization titers against RSV-A.
Time frame: At Day 8 and Day 31 compared to Day 1 (pre-vaccination) in OA groups included in both Phase 1 and Phase 2
Number of participants with RSV-B neutralization titers >= assay cut-off value
Time frame: At Day 1 (pre-vaccination), Day 8 and Day 31 in OA groups included in both Phase 1 and Phase 2
GMTs of RSV-B neutralization titers
Time frame: At Day 1 (pre-vaccination), Day 8 and Day 31 in OA groups included in both Phase 1 and Phase 2
MGI of RSV-B neutralization titers
Time frame: At Day 8 and Day 31 compared to Day 1 (pre-vaccination) in OA groups included in both Phase 1 and Phase 2
SRR against RSV-B
SRR is defined as number of participants having \>=4-fold-increase post-vaccination in neutralization titers against RSV-B.
Time frame: At Day 8 and Day 31 compared to Day 1 (pre-vaccination) in OA groups included in both Phase 1 and Phase 2
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Apr 2029, 34 months after the start.
Of 16 phase 1/2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's planned 34 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Syncytial Virus Infections →